Synonyms: PF 3893787 | PF-03893787 | ZPL-389 | ZPL-3893787 | ZPL389 | ZPL3893787
Comment: Adriforant (ZPL-3893787) was a clinical stage immunomodulatory compound being developed by Ziarco Pharma (a Novartis subsidiary). Mechanistically it is a selective histamine H4 receptor antagonist. Novartis announced in their second-quarter financial report of 2020, that they were terminating the adriforant development programme.
|
|
2D Structure
|
|
Physico-chemical Properties
|
|
Hydrogen bond acceptors
|
6
|
Hydrogen bond donors
|
3
|
Rotatable bonds
|
5
|
Topological polar surface area
|
79.1
|
Molecular weight
|
262.19
|
XLogP
|
1.61
|
No. Lipinski's rules broken
|
0
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
SMILES / InChI / InChIKey
|
|
Canonical SMILES
|
CNC1CCN(C1)c1cc(NCC2CC2)nc(n1)N
|
Isomeric SMILES
|
CN[C@@H]1CCN(C1)c1cc(NCC2CC2)nc(n1)N
|
InChI
|
InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
|
InChI Key
|
ISBHYKVAFKTATD-SNVBAGLBSA-N
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
|